Introduction {#s2}
============

In the last two decades, mortality among children under 5 years old has declined significantly; however, neonatal mortality has not declined as quickly. An estimated 3.1--3.3 million newborns die each year, accounting for 40.3% of under-five mortality [@pmed.1001502-Liu1],[@pmed.1001502-Oestergaard1]. The neonatal mortality rate, the number of newborns dying in the first 28 d of life per 1,000 live births, is estimated globally to be approximately 23.9. In low-middle income African, Eastern Mediterranean, and southeast Asian countries, the neonatal mortality rate ranges from 30.7--35.9, which is substantially greater than in high-income countries where it is estimated to be 3.6 [@pmed.1001502-Oestergaard1].

Neonatal infections, defined as bacteremia/sepsis, pneumonia, and meningitis, cause approximately 23.4% of neonatal deaths worldwide each year [@pmed.1001502-Liu1]. Approximately half of the deaths caused by sepsis or pneumonia occur during the first week of life [@pmed.1001502-Baqui1]. Over the last decade, there has been no measurable reduction in early neonatal mortality [@pmed.1001502-Lawn1]. To develop research priorities and develop strategies for prevention, the mechanisms by which newborns are acquiring infection need to be better understood.

The shared relationship between mothers and their newborns leads to common risk factors and etiologies of infectious diseases. Newborns may acquire early-onset neonatal infection "vertically" (mother-to-newborn during birth) from endogenous bacteria in the mother\'s reproductive tract (hereafter referred to as maternal colonization), which may or may not cause disease in the mother but can cause disease in the newborn. These bacteria, often common colonizers in the maternal vaginal tract, may be transmitted to newborns during the delivery process when newborns come into direct contact with bacterial flora. Ascending infections from the mother to the fetus may occur before or during labour when colonized bacteria from the maternal perineum spread through the vaginal canal, amniotic sac, and into the once-sterile amniotic fluid [@pmed.1001502-AlAdnani1],[@pmed.1001502-Ayengar1]. Amniotic fluid infection, or chorioamnionitis, and bacteremia are additional sources of bacterial transmission from the mother to fetus *in utero*.

In resource-rich settings, interventions such as risk-based antibiotic prophylaxis during labour (based on microbiological screening or risk factors in pregnancy), early diagnosis of sepsis, and neonatal antibiotic treatment have been highly effective in reducing mortality from early-onset neonatal bacterial sepsis [@pmed.1001502-Schrag1]. As a result, in regions with low neonatal mortality levels (less than 15 per 1,000 births), such as the Americas, Europe, and western Pacific, sepsis accounts for 9.1%--15.3% of neonatal deaths [@pmed.1001502-Liu1]. Most of these cases are related to nosocomial infections or prematurity. In contrast, in resource-poor settings where neonatal mortality levels are high (more than 27 per 1,000 births), sepsis accounts for 22.5%--27.2% of neonatal deaths [@pmed.1001502-Liu1]. Interventions such as risk-based prophylaxis are rare or absent, and consequently there is a disproportionately large number of neonatal deaths from sepsis in countries like India, Nigeria, the Democratic Republic of the Congo, Pakistan, and China [@pmed.1001502-Liu1]. Newborns in very high-mortality settings are twice as likely to die from infectious diseases as in low-mortality settings. Despite the heavy burden of disease in high-mortality settings, the risk factors and modes of transmission for neonatal infections have not been well studied in these settings [@pmed.1001502-Bang1].

Several reviews have evaluated the effect of antibiotics on maternal Group B streptococcus (GBS) colonization and maternal risk factors of infection on neonatal sepsis [@pmed.1001502-Cousens1]--[@pmed.1001502-Ohlsson1]. These reviews are limited to randomized controlled trials, predominantly represented high income settings, and focused on specific maternal factors (GBS colonization, prelabour rupture of membranes \[PROM\], preterm prelabour rupture of membranes \[PPROM\]). Antibiotics given to women with PROM reduced the risk of neonatal infection (relative risk \[RR\] = 0.67, 95% CI 0.52--0.85) [@pmed.1001502-Kenyon1]. Similarly, among women with PPROM, antibiotics reduced the risk of neonatal infection (RR = 0.61, CI = 0.48--0.77) [@pmed.1001502-Cousens1]. The evidence for antibiotics given during labour to prevent GBS early-onset neonatal sepsis was inconclusive [@pmed.1001502-Ohlsson1].

This systematic review and meta-analysis estimates the risk of early-onset neonatal infection among newborns of mothers with bacterial infection or colonization compared to newborns of mothers without infection or colonization.

Methods {#s3}
=======

Definitions and Classification {#s3a}
------------------------------

Although laboratory-confirmed infections are considered the gold standard measure of infection, studies with biological samples would be limited in African and southeast Asian countries, causing an underestimate of the effect measure. Rather than restricting our review to studies with only lab-confirmed measures, we also included clinical signs, colonization, and risk factors for infection (maternal only) in order to best estimate the risk of neonatal infection. Including various measures of infection allows us to understand how different measures may affect the estimate. Following PRISMA guidelines ([Text S1](#pmed.1001502.s007){ref-type="supplementary-material"}), we specified these definitions, our methods of analysis, and our inclusion criteria in a protocol *a priori* ([Text S2](#pmed.1001502.s008){ref-type="supplementary-material"}).

We defined our exposure, maternal infection, or colonization during labor, in three categories: (i) Maternal infection: Laboratory-confirmed bacterial infection (hereafter referred to as "lab" and including bacteremia, amnionitis, urinary tract infections, or chorioamnionitis; measured by positive cultures of blood, amniotic fluid, urine, or placental swab; positive PCR---amniotic fluid only; or histopathologically confirmed chorioamnionitis) or clinical signs of infection (hereafter referred to as "signs" and including intrapartum maternal fever, uterine tenderness, maternal tachycardia, malodorous vaginal discharge, elevated white cell count, elevated C-reactive protein, physician diagnosis of clinical chorioamnionitis using a combination of the above signs, or clinical infection undefined). (ii) Maternal colonization: Positive reproductive tract/genital bacterial cultures without signs or symptoms of infection. (iii) Risk factors for infection: PROM (ROM prior to onset of labour ≥37 wk gestation), PPROM (ROM prior to onset of labour \<37 wk gestation), and prolonged ROM (duration of ROM≥18--24 h or undefined).

Pregnant women without infection, reproductive tract colonization, and risk factors for infection were considered the unexposed population. The outcome, early-onset neonatal infection or colonization during the first 7 d of life, was defined in two categories: (i) Neonatal infection: Laboratory confirmed bacterial infection ("lab", including bacteremia, meningitis, urinary tract infection, i.e., positive culture of blood, cerebrospinal fluid, or urine); clinical signs of infection ("signs", including pneumonia, fever, hypothermia, respiratory distress, bradycardia, tachycardia, irritability, lethargy, hypotonia, seizures, poor feeding, oxygen requirement, increased frequency of apnea, poor capillary refill, metabolic acidosis, elevated white cell count, high immature-to-total neutrophil ratio, elevated C-reactive protein, or physician diagnosis of clinical sepsis using a combination of the above signs); laboratory or clinical infection (hereafter referred to as "lab/lab&signs", including a combination of either laboratory-confirmed infection or clinical signs of infection, or undefined). (ii) Newborn colonization: positive ear canal, umbilical, axilla, or anal cultures without signs or symptoms of infection.

We use the term "maternal exposure" as an all-encompassing description of exposures and "neonatal outcome" to describe the outcomes.

The larger aim of performing this review was to determine the potential impact of an intrapartum antibiotic prophylaxis intervention by assessing the risk of vertical transmission of bacterial infection acquired through direct maternal-fetal contact via maternal reproductive tract colonization, chorioamnionitis, or trans-placental transmission (bacteremia). We decided *a priori* not to focus on sexually transmitted infections (such as chlamydia or syphilis) and non-bacterial infections, such as viral (HIV, rubella, cytomegalovirus, or herpes simplex) or parasitic (toxoplasmosis) infections, because they have different mechanisms of transmission.

Search Strategy and Section Criteria {#s3b}
------------------------------------

We searched PubMed (Medline), Embase, Scopus, Web of Science, the Cochrane Library, and the World Health Organization (WHO) Regional Databases (African, eastern Mediterranean, Latin American and Caribbean, western Pacific, and southeast Asian regions). We developed a comprehensive search strategy focusing on three concepts: maternal infection, vertical transmission, and neonatal sepsis. We identified keyword and controlled vocabulary terms applicable to each of these concepts, then combined keywords in each database syntax. We searched studies from January 1, 1960 to March 30, 2013 with no date or language restrictions. We used the search terms as controlled vocabulary in applicable databases and as keywords in all databases ([Table S1](#pmed.1001502.s003){ref-type="supplementary-material"}). We conducted hand searches through the reference lists of screened articles and published systematic reviews and did not find any additional articles. Source articles included publications, abstracts, and conference proceedings available in the public domain. Articles were downloaded and reviewed using EndNote (version ×4).

We included studies of any design that contained raw data or that reported effect measures on the association between maternal exposures and neonatal outcomes, even if early-onset neonatal infection was not the main aim of the study. We excluded reviews, duplicate studies, and studies without a comparison group. We also excluded studies if: the sample size was less than ten; all participants (pregnant women) received antibiotics or steroids; or the infections assessed were nonbacterial infections, tetanus infections, sexually transmitted infections such as chlamydia and syphilis, or TORCH infections (Toxoplasmosis, other, Rubella, Cytomegalovirus, Herpes simplex virus).

Screening and Data Abstraction {#s3c}
------------------------------

Two reviewers independently screened titles, abstracts, and full-text articles using predetermined selection criteria. Two data abstractors independently gathered data from included studies to assess risk of bias, classify exposures and outcomes, obtain published crude or adjusted effect measures, and select raw data to calculate effect measures. One reviewer abstracted study characteristics data. To improve data quality, a second reviewer abstracted study characteristics for a random 10% of the studies with 80% agreement. At each stage, the reviewers compared their results and resolved disagreements by reaching a consensus. We standardized and pilot tested screening and abstraction forms. For articles missing information, we contacted authors to request missing data ([Table S2](#pmed.1001502.s004){ref-type="supplementary-material"}).

We obtained basic data on author, country, study design, and sample size. For potential subgroup analyses, we gathered data on two aspects of each study\'s setting: (1) health facility, multi-center, or community-based, and (2) urban versus rural. The studies provided limited data on intrapartum antibiotic use; we categorized studies according to whether the study had no intrapartum antibiotic use, some antibiotic use, or did not report antibiotic use. We considered early-onset incidence to occur during the first 7 d of life. We also included studies that examined only high risk populations such as preterm labor, PROM, PPROM, and prolonged ROM. To assess variation by region, we grouped studies by WHO region (African, southeast Asia, western Pacific, eastern Mediterranean, European, and American), 2010 World Bank gross national income per capita in US dollars (low, US\$1,005 or less; lower-middle US\$1,006--US\$3,975; upper-middle \$3,976--US\$12,275; high income US\$12,276 or more), and 2009 UNICEF neonatal mortality rates (very low, \<5 deaths per 1,000 live births; low, 5--14 deaths/1,000; high, 15--27 deaths/1,000; and very high, more than 27 deaths/1,000) [@pmed.1001502-World1]--[@pmed.1001502-UNICEF1].

Two independent reviewers assessed the methodological quality of included studies, examining selection methods, missing data, loss-to-follow-up, and confounding bias. Reviewers gave an overall rating of high risk of bias to studies that were high risk in at least one of these domains. Reviewers categorized a study as having a low risk of bias if it qualified as low risk in at least two of these domains and was not high risk in any domain. Reviewers rated studies meeting neither the high risk nor the low risk criteria as having unclear risk.

Statistical Analysis {#s3d}
--------------------

We used the DerSimonian and Laird [@pmed.1001502-DerSimonian1] random-effects meta-analyses to calculate weighted mean estimates across studies and the 95% CI for the odds of neonatal infection among those exposed to maternal infection, colonization, or risk factors for infection, compared to those not exposed (Stata v12). We used the reported odds ratio (OR) and confidence interval for each study. For studies that did not report an OR, we calculated the OR and standard error from raw data. We added a standard correction of 0.5 to zero cells. We assessed measures of heterogeneity with I^2^ statistics if there were three or more studies included in the meta-analysis. For each combination of maternal exposure and neonatal outcome, we calculated a pooled estimate of the OR. Given the substantial heterogeneity across all combinations of maternal exposures and neonatal outcomes, we did not calculate an overall pooled estimate of the ORs.

The studies we examined used numerous combinations of maternal exposure and neonatal outcome. This paper presents the following combinations: (i) maternal lab-confirmed infection and neonatal lab-confirmed infection (lab/lab); (ii) maternal lab-confirmed infection and neonatal clinical signs of infection (lab/signs); (iii) maternal lab-confirmed infection and neonatal lab or clinical infection (lab/lab&signs); (iv) maternal clinical signs of infection and neonatal lab-confirmed infection (signs/lab); (v) maternal clinical signs of infection and neonatal clinical signs of infection (signs/signs); (vi) maternal clinical signs of infection and neonatal lab or clinical infection (signs/lab&signs); (vii) maternal colonization and neonatal lab-confirmed infection (colonization/lab); (viii) maternal colonization and neonatal clinical signs of infection (colonization/signs); (ix) maternal colonization and neonatal lab or clinical infection (colonization/lab&signs); (x) maternal colonization and neonatal colonization (colonization/colonization); (xi) maternal risk factor and neonatal lab-confirmed infection (risk/lab); (xii) maternal risk factor and neonatal clinical signs of infection (risk/signs).

The four forest plots presented in this paper estimate the OR, 95% CI, and relative weights for four different groupings of these combinations: (i--vi) maternal infection and neonatal infection; (vii--ix) maternal colonization and neonatal infection; (x) maternal colonization and neonatal colonization; and (xi--xii) maternal risk factors and neonatal infections. In the forest plots, we report only ORs from cohort studies and nested case-control studies. We omitted un-nested case-control studies since we cannot approximate incidence rate ratios from them. For the studies that provided estimates adjusted for confounding factors, we present sub-group analyses with adjusted measures. These adjusted results are identified by an asterisk in the forest plot figures. In our sensitivity analyses, we repeated the meta-analyses excluding studies with (i) some or unknown intrapartum antibiotics use, (ii) high risk of bias, and (iii) late-onset neonatal cases.

We originally planned for subgroup analyses by region, gross national income per capita in US dollars stratum (low, lower-middle, upper-middle, high income), and neonatal mortality rate stratum (very low, low, high, very high). However, the scarcity of data in the lower income and higher mortality rate countries did not allow for such analyses. Instead, we describe the distribution of studies by region, income, and neonatal mortality rate. We also examined random-effects meta-regression models to investigate the effect of gross national income, neonatal mortality rate, prematurity, region on the risk of vertical transmission, and quality of studies. We repeated these analyses, assessing the effect of explanatory variables on the risk of transmission for early-onset sepsis in studies that specified measurement of infections during the first 7 d of life.

Results {#s4}
=======

Our search identified 4,712 articles of which 3,678 were unique records ([Figure 1](#pmed-1001502-g001){ref-type="fig"}). We reviewed 448 full-text articles including 15 non-English articles ([Table S3](#pmed.1001502.s005){ref-type="supplementary-material"}). Eighteen authors were emailed regarding missing data and provided with a sample 2×2 table to complete. Four authors responded and one [@pmed.1001502-Pylipow1] provided usable data. Data from 83 studies met the inclusion criteria. Our qualitative analysis included all 83 studies; our quantitative meta-analysis included 67 of them ([Figure 1](#pmed-1001502-g001){ref-type="fig"}). Nine studies used definitions of maternal exposures or neonatal outcomes that were too heterogeneous to combine in the meta-analysis [@pmed.1001502-Ayengar1],[@pmed.1001502-Kalinka1]--[@pmed.1001502-Vergani1]; these studies had ORs of neonatal outcomes among those maternally exposed compared to those unexposed between 0.5 and 194.6. Six studies used a case-control design and were excluded from the meta-analyses [@pmed.1001502-Bhutta1]--[@pmed.1001502-Oddie1]. These six case-control studies had higher ORs than the cohort/nested case-control studies. Andrews et al. (2008) contained two zero cells and was dropped in the meta-analysis [@pmed.1001502-Andrews1]. The majority of studies used cohort designs (*n* = 75, 90.4%) based in single health facilities (*n* = 64, 77.1%).

![Flow diagram of study selection.](pmed.1001502.g001){#pmed-1001502-g001}

[Table 1](#pmed-1001502-t001){ref-type="table"} describes the number of studies and study characteristics in each meta-analysis. In 60 studies (72.3%), researchers measured early-onset neonatal infection outcomes during the first 7 d of life. Seventeen studies (20.5%) had data on women who all similarly did not receive intrapartum antibiotics (either the study cohort did not use antibiotics, the study excluded women who received antibiotics, or data were abstracted from the placebo arm of an intervention trial); 35 studies (42.2%) reported some antibiotic use in an undefined subset of women; and 31 studies (37.3%) did not specify whether antibiotics were used. Twenty-two of the studies (26.5%) restricted their sample to a specific target population (preterm labor, PROM, or PPROM), while the majority of studies (*n* = 61, 73.5%) evaluated all pregnant women. Most studies (*n* = 62, 74.7%) were conducted in the Americas or Europe, nine studies (10.8%) were in the western Pacific, four studies (4.8%) were in southeast Asia, six studies (7.2%) were in the eastern Mediterranean region, and two studies (2.4%) were in Africa. Most studies were in high income (*n* = 66, 79.5%) and very low mortality (*n* = 67, 80.7%) settings ([Table 1](#pmed-1001502-t001){ref-type="table"}). A study could report more than one type of maternal exposure or neonatal outcome but appeared only once in each meta-analysis. [Table 2](#pmed-1001502-t002){ref-type="table"} lists additional details of each study. [Table S4](#pmed.1001502.s006){ref-type="supplementary-material"} reports the exposure and outcome definitions for each study. To assess for publication and small-study bias, we used funnel plots of standard error and effect size to determine the correlation between the variance and distribution of effect sizes ([Figure S1](#pmed.1001502.s001){ref-type="supplementary-material"}). These results were not statistically significant (*p* = 0.07).

10.1371/journal.pmed.1001502.t001

###### Characteristics of included studies.

![](pmed.1001502.t001){#pmed-1001502-t001-1}

  Characteristics                                            Total (All Studies)    Maternal Infections and Neonatal Infections   Maternal Colonization and Neonatal Infections   Maternal Colonization and Neonatal Colonization   Maternal Risk Factors and Neonatal Infections
  --------------------------------------------------------- ---------------------- --------------------------------------------- ----------------------------------------------- ------------------------------------------------- -----------------------------------------------
  **Number of studies**                                                                                                                                                                                                            
  Number of studies total (qualitative and meta-analysis)             83                                34                                             22                                               25                                               14
  Number of studies in the meta-analysis                              67                                29                                             16                                               25                                               10
  Study sample size, median (25th, 75th percentile)          500 (IQR 131--1,516)                180 (IQR 81--728)                           1,239 (IQR 869--2,108)                            632 (IQR 251--1,039)                             887 (IQR 143--1,413)
  **Study type**                                                                                                                                                                                                                   
  Cohort (including RCTs)                                         75 (90.4%)                        28 (82.4%)                                     20 (90.9%)                                        25 (100%)                                        9 (64.3%)
  Nested case-control                                              2 (2.4%)                          1 (2.9%)                                       1 (4.6%)                                            ---                                           1 (7.1%)
  Case-control                                                     6 (7.2%)                          5 (14.7%)                                      1 (4.6%)                                            ---                                           4 (28.6%)
  **Location**                                                                                                                                                                                                                     
  Health facility                                                 64 (77.1%)                        26 (76.5%)                                     16 (72.7%)                                       20 (80.0%)                                       10 (71.4%)
  Multi-center                                                    17 (20.5%)                         7 (20.6%)                                      6 (27.3%)                                        4 (16.0%)                                        4 (28.6%)
  Unknown or not clear                                             2 (2.4%)                          1 (2.9%)                                          ---                                           1 (4.0%)                                            ---
  **Urban or rural**                                                                                                                                                                                                               
  Urban or periurban                                              71 (85.5%)                        30 (88.2%)                                     17 (77.3%)                                       21 (84.0%)                                       12 (85.7%)
  Mixed (urban/rural)                                              1 (1.2%)                          1 (2.9%)                                          ---                                              ---                                              ---
  Unknown or not clear                                            11 (13.3%)                         3 (8.8%)                                       5 (22.7%)                                        4 (16.0%)                                        2 (14.7%)
  **Timing of early-onset sepsis**                                                                                                                                                                                                 
  First 7 d of life                                               60 (72.3%)                        20 (58.8%)                                     16 (72.7%)                                        23 (92.0)                                       13 (92.9%)
  Not reported or unclear                                         23 (27.7%)                        14 (41.2%)                                      6 (27.3%)                                        2 (8.0%)                                         1 (7.1%)
  **Antibiotic use**                                                                                                                                                                                                               
  No intrapartum antibiotic use                                   17 (20.5%)                         4 (11.8%)                                      6 (27.3%)                                        4 (16.0%)                                           ---
  Some intrapartum antibiotic use                                 35 (42.2%)                        19 (55.9%)                                     10 (45.5%)                                        7 (28.0%)                                       10 (71.4%)
  Unknown or not clear                                            31 (37.3%)                        11 (32.4%)                                      6 (27.3%)                                       14 (56.0%)                                        4 (28.6%)
  **High risk population**                                                                                                                                                                                                         
  Preterm                                                          7 (8.4%)                          7 (20.6%)                                         ---                                              ---                                           3 (21.4%)
  PROM                                                             1 (1.2%)                          1 (2.9%)                                          ---                                              ---                                           1 (7.1%)
  PPROM                                                           9 (10.8%)                          7 (20.6%)                                      1 (4.6%)                                            ---                                              ---
  Preterm or PROM                                                  4 (4.8%)                          2 (5.9%)                                       2 (9.1%)                                            ---                                           1 (7.1%)
  None, all women included                                        61 (73.5%)                        17 (50.0%)                                     19 (86.4%)                                       24 (96.0%)                                        9 (64.3)
  Other or unclear                                                 1 (1.2%)                             ---                                            ---                                           1 (4.0%)                                            ---
  **WHO Region**                                                                                                                                                                                                                   
  Africa                                                           2 (2.4%)                             ---                                            ---                                           1 (4.0%)                                         1 (7.1%)
  Americans                                                       29 (34.9%)                        15 (44.1%)                                     10 (45.5%)                                        3 (12.0%)                                        4 (28.6%)
  Eastern Mediterranean                                            6 (7.2%)                          3 (8.8%)                                       1 (4.6%)                                         3 (12.0%)                                        2 (14.3%)
  Europe                                                          33 (39.8%)                        11 (32.4%)                                      6 (27.3%)                                       14 (56.0%)                                        5 (35.7%)
  Southeast Asia                                                   4 (4.8%)                          1 (2.9%)                                       3 (13.6%)                                           ---                                           1 (7.1%)
  Western Pacific                                                 9 (10.8%)                          4 (11.8%)                                      2 (9.1%)                                         4 (16.0%)                                        1 (7.1%)
  **Neonatal mortality range**                                                                                                                                                                                                     
  Very low mortality \<5 per 1,000 live births                    67 (80.7%)                        29 (85.3%)                                     17 (77.3%)                                       18 (72.0%)                                       10 (71.4%)
  Low mortality 5--14                                              6 (7.2%)                          1 (2.9%)                                       1 (4.6%)                                         5 (20.0%)                                           ---
  High mortality 15--27                                            3 (3.6%)                          2 (5.9%)                                       1 (4.6%)                                         1 (4.0%)                                         1 (7.1%)
  Very high mortality \>27                                         7 (8.4%)                          2 (5.9%)                                       3 (13.6%)                                        1 (4.0%)                                         3 (21.4%)
  **Income range**                                                                                                                                                                                                                 
  High income (≥US\$12,276) per capita                            66 (79.5%)                        29 (85.3%)                                     17 (77.3%)                                       17 (68.0%)                                       10 (78.6%)
  Upper middle income (US\$3,976--US\$12,275)                      8 (9.6%)                          1 (2.9%)                                       1 (4.6%)                                         7 (28.0%)                                           ---
  Lower middle income (US\$1,006--US\$3,975)                       8 (9.6%)                          4 (11.8%)                                      4 (18.2%)                                        1 (4.0%)                                         3 (21.4%)
  Low income (≤US\$1,005)                                          1 (1.2%)                             ---                                            ---                                              ---                                           1 (7.1%)

Numbers provided are *n* (%) unless otherwise specified. IQR, interquartile range; RCT, randomized controlled trial.

10.1371/journal.pmed.1001502.t002

###### Studies included in the systematic review and meta-analysis.

![](pmed.1001502.t002){#pmed-1001502-t002-2}

  Ref \#          Author         Year     Years Conducted         Country       Study Sample Size       Study Type            Setting       Urban or Rural   Timing of EOS Diagnosis   Antibiotic Use   Specialized Population   WHO Region[a](#nt102){ref-type="table-fn"}   Neonatal Mortality Rate (per 1,000 Live Births)   Income (USD)
  -------- -------------------- ------ ---------------------- ---------------- ------------------- --------------------- ----------------- ---------------- ------------------------- ---------------- ------------------------ -------------------------------------------- ------------------------------------------------- --------------
  96             Barcaite        2012        2006--2007          Lithuania             998                Cohort          Health facility       Urban                ≤7 days                Used                 All                                EUR                                              3                             11,390
  26              Chemsi         2012        2009--2011           Morocco              99              Case-control       Health facility       Urban               \>7 days              Unknown                All                                EMR                                             20                             2,850
  28           Emamghorashi      2012           2010                Iran               114             Case-control       Health facility       Urban                ≤7 days              Unknown                All                                EMR                                             19                             2,500
  100             Huang          2012           2005               Taiwan              92                 Cohort          Health facility       Urban                ≤7 days              Unknown                All                                WPR                                              4                             41,385
  29               Kovo          2012        2007--2009            Israel              120             Case-control       Health facility       Urban                ≤7 days                Used                 All                                EUR                                              2                             27,170
  47               Lee           2012        2005--2010          Hong Kong             212                Cohort          Health facility       Urban                ≤7 days                Used                 All                                WPR                                              1                             51,490
  62              Tudela         2012        2000--2008             USA              143,384              Cohort           Multi-center         Urban                ≤7 days                Used                 All                                AMR                                              4                             47,390
  64            Wojkowska        2012           2009               Poland              910                Cohort           Multi-center         Urban               \>7 days                Used                 All                                EUR                                              4                             12,440
  66              Kordek         2011           n/a                Poland              286                Cohort          Health facility       Urban                ≤7 days                Used                 All                                EUR                                              4                             12,440
  75              Kunze          2011      Jan--Dec 2004          Germany              869                Cohort          Health facility       Urban                ≤7 days                Used                 All                                EUR                                              2                             43,110
  57             Puopolo         2011        1993--2007             USA               1,413         Nested case-control    Multi-center        Unknown               ≤7 days                Used                 All                                AMR                                              4                             47,390
  99        Bourgeois-Nicolaos   2010    Jan 2004--Dec 2004        France             1,139               Cohort          Health facility       Urban                ≤7 days              Unknown                All                                EUR                                              2                             42,390
  56              Dutta          2010           n/a                India               728                Cohort          Health facility       Urban                ≤7 days                Used               Preterm                              SEAR                                            34                             1,330
  74               Faro          2010    Jan 2003--Dec 2004         USA               2,108               Cohort           Multi-center         Urban                ≤7 days                Used                 All                                AMR                                              4                             47,390
  48              Kasper         2010        June 2001            Austria              118                Cohort          Health facility       Urban                ≤7 days              Unknown              Preterm                              EUR                                              2                             47,060
  95              Seoud          2010    Feb 2004--Sep 2004       Lebanon              779                Cohort           Multi-center         Urban               \>7 days                Used                 All                                EMR                                              7                             8,880
  101           Tameliene        2010        2006--2007          Lithuania             970                Cohort          Health facility      Unknown               ≤7 days              Unknown                All                                EUR                                              3                             11,390
  94             Elzbieta        2009    Jan 2008--Mar 2008        Poland              100                Cohort          Health facility      Unknown               ≤7 days                Used                 All                                EUR                                              4                             12,440
  98              Pinter         2009      Jun--Dec 2005            USA                317                Cohort          Health facility       Urban                ≤7 days              Unknown                All                                AMR                                              4                             47,390
  31             Andrews         2008    Jul 2003--Jun 2006         USA               5,732               Cohort          Health facility       Urban                ≤7 days              Unknown                All                                AMR                                              4                             47,390
  46            Goldenberg       2008        1996--2001             USA                351                Cohort          Health facility      Unknown               ≤7 days              Unknown              Preterm                              AMR                                              4                             47,390
  73         Namavar Jahromi     2008      Apr--Sep 2003            Iran              1,197               Cohort          Health facility       Urban                ≤7 days                Used                 All                                EMR                                             19                             2,500
  93              Lijoi          2007    Nov 2003--Nov 2004        Italy              2,158               Cohort          Health facility       Urban                ≤7 days              Not used               All                                EUR                                              2                             35,150
  21            Muthusami        2007    May 2006--Jul 2006        India               77                 Cohort          Health facility       Urban                ≤7 days              Unknown                All                                SEAR                                            34                             1,330
  17             Kalinka         2006    May 2001--Dec 2002        Poland              120                Cohort          Health facility       Urban                ≤7 days              Not used               All                                EUR                                              4                             12,440
  65              Kordek         2006           n/a                Poland              46                 Cohort          Health facility       Urban                ≤7 days                Used           Preterm or PROM                          EUR                                              4                             12,440
  19              Kunze          2006    Jan 2011--Dec 2002       Germany             1,438               Cohort          Health facility       Urban                ≤7 days                Used                 All                                EUR                                              2                             43,110
  92               Eren          2005    May 2000--Jan 2001        Turkey              500                Cohort          Health facility       Urban                ≤7 days              Unknown               Other                               EUR                                             12                             9,890
  55            Ronnestad        2005        1999--2000            Norway            119,611              Cohort           Multi-center         Urban                ≤7 days                Used               Preterm                              EUR                                              2                             84,290
  102            Kafetzis        2004    Jun 2000--Dec 2001        Greece              251                Cohort          Health facility       Urban                ≤7 days              Unknown                All                                EUR                                              2                             26,940
  91              Tsolia         2003    Jan 2000--May 2000        Greece             1,014               Cohort           Multi-center         Urban                ≤7 days                Used                 All                                EUR                                              2                             26,940
  63             Dollner         2002           1999               Norway              221                Cohort          Health facility       Urban                ≤7 days                Used                 All                                EUR                                              2                             84,290
  90             El-Kersh        2002    Jan 1963--Jul 1965     Saudi Arabia           217                Cohort          Health facility       Urban                ≤7 days              Not used               All                                EMR                                             12                             16,720
  30              Oddie          2002    Apr 1988--Mar 2000          UK              62,786            Case-control        Multi-center        Unknown               ≤7 days                Used                 All                                EUR                                              3                             38,370
  24             Vergani         2002        1991--1994             USA              32,630               Cohort          Health facility       Urban                ≤7 days              Not used               All                                AMR                                              4                             47,390
  80            Volumenie        2001    Jan 1994--Sep 1996        France             5,374               Cohort          Health facility       Urban               \>7 days                Used                 All                                EUR                                              2                             42,390
  78                Ma           2000    Dec 1997--Dec 1998        China               768                Cohort          Health facility       Urban                ≤7 days              Unknown                All                                WPR                                             11                             4,270
  45               Yoon          2000           n/a             South Korea            315                Cohort          Health facility       Urban                ≤7 days              Unknown              Preterm                              WPR                                              2                             17,890
  27            Cukrowska        1999           n/a            Czech Republic          148             Case-control       Health facility       Urban                ≤7 days                Used               Preterm                              EUR                                              2                             17,890
  89             Hickman         1999    Jan 1994--Feb 1995         USA                546                Cohort           Multi-center         Urban                ≤7 days                Used                 All                                AMR                                              4                             47,390
  61              Mercer         1999    Jul 1997--Feb 1998         USA               8,474               Cohort           Multi-center         Urban                ≤7 days                Used                 All                                AMR                                              4                             47,390
  72              Piper          1999    Jan 1992--Jun 1994         USA               1,046               Cohort          Health facility       Urban               \>7 days                Used                 All                                AMR                                              4                             47,390
  25              Bhutta         1997    Jan 1990--Dec 1993       Pakistan             38              Case-control       Health facility       Urban                ≤7 days              Unknown                All                                EMR                                             42                             1,050
  79              Mercer         1997    Feb 1992--Jan 1995         USA               1,867               Cohort           Multi-center        Unknown               ≤7 days              Not used              PPROM                               AMR                                              4                             47,390
  54           Papantoniou       1997    Feb 1993--Jun 1994        Greece              32                 Cohort          Health facility       Urban               \>7 days                Used                PPROM                               EUR                                              2                             26,940
  88             Sensini         1997    Mar 1993--Sep 1995        Italy              2,300               Cohort          Health facility       Urban                ≤7 days              Unknown                All                                EUR                                              2                             35,150
  77             Itakura         1996    Jul 1987--Dec 1992        Japan              1,280               Cohort          Health facility       Urban                ≤7 days              Unknown                All                                WPR                                              1                             41,850
  97             Mitsuda         1996    Jul 1991--Jun 1992        Japan               466                Cohort          Health facility       Urban                ≤7 days              Unknown                All                                WPR                                              1                             41,850
  71              Regan          1996        1984--1989             USA              13,646               Cohort           Multi-center         Urban               \>7 days              Not used               All                                AMR                                              4                             47,390
  43             Averbuch        1995           n/a                Israel              90                 Cohort          Health facility       Urban               \>7 days              Unknown               PPROM                               EUR                                              2                             27,170
  44             Matsuda         1995      Feb--Oct 1992           Japan               41                 Cohort          Health facility       Urban               \>7 days              Unknown              Preterm                              WPR                                              1                             41,850
  60             Rosemond        1995    Jun 1989--Dec 1993         USA                224                Cohort          Health facility       Urban               \>7 days                Used                PPROM                               AMR                                              4                             47,390
  86              Ayata          1994           n/a                Turkey              114                Cohort          Health facility       Urban                ≤7 days              Unknown                All                                EUR                                             12                             9,890
  53            de Araujo        1994           1991               Brazil              223                Cohort          Health facility       Urban                ≤7 days                Used                 All                                AMR                                             12                             9,390
  42             Gauthier        1994           n/a                 USA                225                Cohort          Health facility       Urban               \>7 days              Not used              PPROM                               AMR                                              4                             47,390
  16             Pylipow         1994    Jan 1991--Sep 1992         USA               2,040               Cohort          Health facility       Urban                ≤7 days                Used                 All                                AMR                                              4                             47,390
  87              Suara          1994    May 1992--Feb 1993        Gambia              196                Cohort          Health facility      Unknown               ≤7 days              Unknown                All                                AFR                                             32                             7,740
  52             Puchner         1993           n/a               Austria              80                 Cohort              Unknown          Unknown              \>7 days              Not used               All                                EUR                                              2                             47,060
  70              Burman         1992           n/a                Sweden             4,559               Cohort           Multi-center        Unknown              \>7 days              Not used               All                                EUR                                              2                             50,110
  6              Ayengar         1991           n/a                India              1,792               Cohort          Health facility       Urban                ≤7 days              Unknown                All                                SEAR                                            34                             1,330
  51              Dudley         1991    Feb 1988--Jul 1990      Australia             81                 Cohort          Health facility       Urban                ≤7 days                Used                PPROM                               WPR                                              3                             46,320
  69              Towers         1990    Jan 1989--Jul 1989         USA                131                Cohort          Health facility       Urban               \>7 days                Used           Preterm or PROM                          AMR                                              4                             47,390
  85              Kollee         1989    Apr 1986--Jan 1987     Netherlands            632                Cohort          Health facility       Urban                ≤7 days              Unknown                All                                EUR                                              3                             49,050
  20             Morales         1989   Jan 1 1986--Mar 1988        USA                212                Cohort           Multi-center         Urban               \>7 days              Not used              PPROM                               AMR                                              4                             47,390
  59              Newton         1989      Apr--Dec 1986            USA               2,908               Cohort          Health facility       Urban               \>7 days                Used                 All                                AMR                                              4                             47,390
  23           Tuppurainen       1989    Dec 1983--Jan 1986       Finland             8,977               Cohort          Health facility       Urban                ≤7 days              Not used               All                                EUR                                              2                             47,720
  18             Kishore         1987           n/a                India               109                Cohort          Health facility       Urban                ≤7 days              Not used               All                                SEAR                                            34                             1,330
  41            Feinstein        1986    Jul 1983--Apr 1985         USA                146                Cohort          Health facility       Urban               \>7 days              Not used               PROM                               AMR                                              4                             47,390
  84              Liang          1986    Sep 1983--Mar 1984      Hong Kong             168                Cohort          Health facility       Urban                ≤7 days              Not used               All                                WPR                                              1                             51,490
  22             Persson         1986    Sep 1983--Oct 1984        Sweden             1,786         Nested case-control   Health facility       Urban                ≤7 days                Used                 All                                EUR                                              2                             50,110
  76              Bobitt         1985           n/a                 USA                937                Cohort          Health facility       Urban               \>7 days                Used                 All                                AMR                                              4                             47,390
  40           Broekhuizen       1985    Jul 1981--Dec 1983         USA                53                 Cohort          Health facility       Urban               \>7 days              Unknown               PPROM                               AMR                                              4                             47,390
  50             McGrady         1985        1980--1981             USA               1,342               Cohort           Multi-center         Mixed               \>7 days              Unknown                All                                AMR                                              4                             47,390
  83             Visconti        1985    Apr 1980--Jan 1983        Italy              1,516               Cohort           Multi-center         Urban               \>7 days              Unknown                All                                EUR                                              2                             35,150
  82            Weintraub        1983           n/a                Israel              385                Cohort          Health facility       Urban                ≤7 days              Unknown                All                                EUR                                              2                             27,170
  68           Christensen       1982    Nov 1979--Jun 1980        Sweden              300                Cohort          Health facility      Unknown               ≤7 days              Unknown                All                                EUR                                              2                             50,110
  39               Pass          1982    Jul 1977--Jun 1980         USA                68                 Cohort           Multi-center         Urban               \>7 days                Used                 All                                AMR                                              4                             47,390
  58              Wilson         1982    Sep 1978--Aug 1980         USA                143                Cohort          Health facility       Urban                ≤7 days                Used                PPROM                               AMR                                              4                             47,390
  67              Boyer          1981    Sep 1977--Apr 1979         USA                924                Cohort          Health facility       Urban                ≤7 days              Not used         Preterm or PROM                          AMR                                              4                             47,390
  81            Merenstein       1980           n/a                 USA               1,815               Cohort              Unknown          Unknown               ≤7 days              Not used               All                                AMR                                              4                             47,390
  103             Tafari         1979        1975--1978           Ethiopia            1,351               Cohort          Health facility       Urban                ≤7 days              Unknown                All                                AFR                                             36                              390
  38              Bobitt         1977    Oct 1974--May 1975         USA                12                 Cohort          Health facility       Urban               \>7 days              Unknown          Preterm or PROM                          AMR                                              4                             47,390
  49              Elder          1971           n/a                 USA               9,156               Cohort          Health facility       Urban               \>7 days              Not used               All                                AMR                                              4                             47,390

WHO regions: AFR: Africa; AMR: Americas; EMR: Eastern Mediterrean; EUR: Europe; SEAR: Southeast Asia; WPR: Western Pacific.

Regional {#s4a}
--------

Available data on laboratory cultures, clinical signs, colonization status, and risk factors varied by region. The Americas, Europe and eastern Mediterranean regions had studies that examined all of the above measures of maternal exposure. None of the studies in Africa provided lab-confirmed maternal infection data or clinical signs data. No study in southeast Asia provided lab-confirmed data. We were able to find studies in every region that provided data on maternal colonization and risk factors for infection, although the majority were from Europe and the Americas. All regions presented data on neonatal lab-confirmed infection, with the majority in the Americas. None of the studies in Africa or the eastern Mediterranean region had neonatal clinical signs of infection. No study in southeast Asia had neonatal colonization data.

Risk of Bias {#s4b}
------------

After assessing attrition bias, selection bias, and confounding bias across the 83 studies, we rated two studies (2.4%) as having low risk, 53 (63.9%) as having unclear risk, and 28 (33.7%) as having high risk of bias ([Figure S2](#pmed.1001502.s002){ref-type="supplementary-material"}). Among the 83 studies, 15 (18.1%) studies were considered as being at high risk for attrition bias. These studies lost more than 10% of participants to follow-up or had differential follow-up between the exposed and comparison groups. Thirteen (15.7%) studies had evidence of selection bias, defined as differential selection of the exposed and comparison groups resulting in a difference in the distribution of risk factors. Sixteen (19.3%) studies were rated as being at high risk for confounding bias, defined as a lack of adjustment for potential confounders through study design or statistical adjustment.

Meta-analyses {#s4c}
-------------

The meta-analyses results are presented by exposure outcome combinations: (i) maternal infection and neonatal infection; (ii) maternal colonization and neonatal infection; (iii) maternal colonization and neonatal colonization; and (iv) maternal risk factors and neonatal clinical infection.

### Maternal infection and neonatal infection {#s4c1}

Twenty-nine studies reported data on maternal infections and neonatal infections. As shown in [Figure 2](#pmed-1001502-g002){ref-type="fig"}, studies that tested lab cultures for infection in both mother and newborn ("lab/lab"), newborns of infected mothers had a 6.6 (95% CI 3.9--11.2) times greater odds of infection than newborns of uninfected mothers. In studies that diagnosed maternal infection with clinical signs and neonatal infection with lab tests ("signs/lab"), newborns of infected mothers had a 7.7 (95% CI 4.6--13.0; I^2^ = 72.0%, 95% CI 45%--86%; adjusted OR 5.2, 95% CI 1.6--16.6; I^2^ = 77.1%, 95% CI 25%--93%) times greater odds of infection than newborns of uninfected mothers. Studies that diagnosed neonatal infection with lab tests or clinical signs ("lab/lab&signs"; "signs/lab&signs") had a greater OR than those that diagnosed neonatal infection with only lab or only clinical signs ("lab/lab"; "lab/signs"; "signs/lab"; "signs/signs") ([Figure 2](#pmed-1001502-g002){ref-type="fig"}).

![Maternal infection and neonatal infection.\
\*Adjusted ORs. These studies provided estimates adjusted for confounding factors.](pmed.1001502.g002){#pmed-1001502-g002}

Sensitivity analyses excluding studies with a high risk of bias increased the ORs to 9.3 (95% CI 5.1--16.9) for the "lab/lab" analysis and slightly decreased the OR to 6.2 (95% CI 1.7--23.1) for the "signs/lab" analysis. Excluding studies with a high risk of confounding bias yielded ORs of 9.1 (95% CI 2.4--34.0) and 7.7 (95% CI 4.6--13.0) for "lab/lab" and "signs/lab" analyses, respectively. We also conducted a sensitivity analysis including only studies that clearly defined early-onset neonatal sepsis during the first 7 d of life. The ORs increased to 10.2 (95% CI 5.3--19.5) and 8.3 (95% CI 4.5--15.1) for "lab/lab" and "signs/lab" analyses, respectively. We did not have sufficient data to conduct a sensitivity analysis subgrouping studies with known or unknown antibiotic use.

### Maternal colonization and neonatal infection {#s4c2}

Given the heterogeneity of the data, we focused on GBS maternal colonization. Sixteen studies reported data on GBS maternal colonization and neonatal infection.

As shown in [Figure 3](#pmed-1001502-g003){ref-type="fig"}, in studies that tested GBS bacterial colonization in the mother and lab cultures for infection in the newborn ("colonization/lab"), newborns of colonized mothers had a 9.4 (95% CI 3.1--28.5; I^2^ = 76.3%, 95% CI 58%--87%) times greater odds of having infection than newborns of non-colonized mothers. A sensitivity analysis excluding studies with high risk of bias increased the ORs to 13.7 (95% CI 4.2--45.1). Excluding studies without a specified early-onset period to measure neonatal infection increased the odds to 11.0 (95% CI 2.3--54.0). A sensitivity analysis including only studies in which no antibiotics were used also increased the OR to 37.0 (95% CI 9.7--140.9).

![Maternal GBS colonization and neonatal infection.](pmed.1001502.g003){#pmed-1001502-g003}

In studies that tested lab cultures for infection in newborns ("colonization/lab"), newborns of colonized mothers had higher odds of developing infection compared to those in studies that diagnosed neonatal infection clinical signs ("colonization/signs") or that diagnosed neonatal infection with both lab tests and clinical signs ("colonization/lab &signs") ([Figure 3](#pmed-1001502-g003){ref-type="fig"}).

### Maternal colonization and neonatal colonization {#s4c3}

Twenty-five studies reported data on maternal colonization and neonatal colonization. We present these results by pathogen-specific subgroups: GBS, *Staphylococcus aureus*, *Escherichia coli*, and *Ureaplasma* ([Figure 4](#pmed-1001502-g004){ref-type="fig"}). In studies that cultured GBS colonization for both the mother and newborn, newborns of colonized mothers had a 28.6 (95% CI 13.2--62.1; I^2^ = 88.8%, 95% CI 84%--92%) times higher odds of colonization compared to newborns of non-colonized mothers.

![Maternal colonization and neonatal colonization.](pmed.1001502.g004){#pmed-1001502-g004}

A sensitivity analysis excluding high risk studies showed an increased OR to 43.8 (95% CI 11.0--174.8). Excluding studies that did not specify an early-onset neonatal infection period had a similar OR of 29.4 (95% CI 11.9--72.5, I^2^ = 89.1%, 95% CI 84%--92%). The OR for *Staphylococcus aureus* colonization was 7.5 (95% CI 2.9--19.1). The OR for *E. coli* colonization was 1.8 (95% CI 1.3--2.6). One study measured *Ureaplasma* colonization, which had lower ORs compared to studies measuring GBS or *S. Aureus* colonization ([Figure 4](#pmed-1001502-g004){ref-type="fig"}).

### Maternal risk factors and neonatal infection {#s4c4}

Ten studies presented data on maternal risk factors (PPROM, PROM, prolonged ROM) and neonatal infections ([Figure 5](#pmed-1001502-g005){ref-type="fig"}). In studies that observed risk factors for infection in the mother and tested lab cultures for the newborn ("risk/lab"), newborns of mothers with risk factors had a 2.3 (95% CI 1.0--5.4; I^2^ = 93.4%, 95% CI 89%--96%; adjusted OR 4.9, 95% CI 1.9--12.8) times greater odds of having infection than newborns of mothers without risk factors for infection. In two non-adjusted studies that classified PPROM as a risk factor for maternal infection and tested neonatal lab cultures for the newborn, newborns of mothers with PPROM had a 1.5 (95% CI 0.9--2.4) times greater odds of having an infection than newborns of mothers without PPROM, which was not statistically significant. In four non-adjusted studies that examined the risk factor ROM≥18--24 h, newborns of mothers with prolonged ROM had a 2.2 (95% CI 0.6--7.4) higher odds of having an infection than newborns of mothers with ROM\<18 h, which was not statistically significant.

![Maternal risk factors and neonatal infection.\
\*Adjusted ORs. These studies provided estimates adjusted for confounding factors.](pmed.1001502.g005){#pmed-1001502-g005}

Sensitivity analysis excluding high risk of bias studies, in studies that observed risk factors for infection in the mother and tested lab cultures for the newborn ("risk/lab"), had a similar OR of 2.2 (95% CI 0.8--2.4). Similar results were seen after excluding studies without a specified early-onset neonatal sepsis period.

Meta-regression {#s4d}
---------------

We used meta-regression to explore the effect of potential explanatory variables on the risk of vertical transmission, including: neonatal mortality rate, gross national income, prematurity, antibiotic use, WHO region, and risk of bias in each of the four groups: maternal infection and neonatal infection, maternal colonization and neonatal infection, maternal colonization and neonatal colonization, and maternal risk factors and neonatal infection. The coefficients of all these potential explanatory variables were non-significant in the crude and adjusted analyses because of small sample sizes ([Table 3](#pmed-1001502-t003){ref-type="table"}).

10.1371/journal.pmed.1001502.t003

###### Regression analysis of the effect of explanatory variables on the risk of transmission (early-onset).

![](pmed.1001502.t003){#pmed-1001502-t003-3}

  Variables                                       Maternal Infection/Neonatal Infection (*n* = 16)   Maternal Colonization/Neonatal Infection (*n* = 14)   Maternal Colonization/Neonatal Colonization (*n* = 24)   Maternal Risk Factors/Neonatal Infection (*n* = 9)                                                                                                                                 
  ---------------------------------------------- -------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------- ------ ---- ------- ------ ------------- ------ ---- ------- -------- ---------------- ------ --- ------- ------ ------------- ------
  **NMR**                                                                                                                                                                                                                                                                                                                                                                                              
  Very low mortality \<5 per 1,000 live births                           14                                                                                                         ref                                                                                         9            ref                         18            ref                             7           ref                 
  Low mortality 5--14                                                    1                                                  0.96                                                    2.61                                               0.34--20.12                       0.33   1    −1.27   0.28   0.01--7.68    0.41   4    0.81     2.24     0.22--22.43     0.47   0           ---                 
  High mortality 15--27                                                  0                                                                                                          ---                                                                                         1    −0.50   0.61   0.01--58.87   0.81   1    4.93    139.06   2.08--9,312.79   0.02   0           ---                 
  Very high mortality \>27                                               1                                                  −0.06                                                   0.94                                                0.11--7.75                       0.95   3    0.47    1.61   0.10--25.58   0.71   1    −1.61    0.20      0.01--7.79     0.37   2   −0.85   0.43   0.08--0.26    0.26
  **Gross national income**                                                                                                                                                                                                                                                                                                                                                                            
  High income (≥12,276) per capita in USD                                14                                                                                                         ref                                                                                         9            ref                         16            ref                             7           ref                 
  Upper middle income (3,976--12,275)                                    1                                                  0.96                                                    2.61                                               0.34--20.12                       0.33   1    −1.26   0.28   0.01--6.41    0.39   7    −1.02    0.36      0.07--1.80     0.20   0           ---                 
  Lower middle income (1,006--3,975)                                     1                                                  −0.06                                                   0.94                                                0.11--7.75                       0.95   4    0.24    1.27   0.12--13.54   0.83   1    4.60    99.78     6.26--39.49     0.03   1   0.99    2.69   0.53--13.67   0.19
  Low income (≤1,005)                                                    0                                                                                                          ---                                                                                         0            ---                         0             ---                             1   −2.02   0.13   0.06--0.32    0.00
  **Antibiotics**                                                                                                                                                                                                                                                                                                                                                                                      
  None                                                                   0                                                                                                                                                                                                      4            ref                         4             ref                             0                               
  Some                                                                   13                                                                                                         ref                                                                                         5    0.26    1.29   0.08--19.72   0.84   7    1.42     4.15     0.27--63.06     0.29   7           ref                 
  Unknown                                                                3                                                  −0.58                                                   0.56                                               1.41--20.12                       0.20   5    −0.56   0.57   0.05--7.10    0.64   13   0.44     1.56     0.13--18.63     0.71   2   −1.19   0.30   0.07--1.42    0.11
  **Gestational age**                                                                                                                                                                                                                                                                                                                                                                                  
  All                                                                    8                                                                                                          ref                                                                                         12                                       24            ---                             5           ref                 
  Premature                                                              8                                                  −0.72                                                   0.49                                               0.99--20.12                       0.05   2    −0.61   0.54   0.03--10.29   0.66   0                                             4   0.12    1.13   0.18--6.98    0.88
  **WHO Region**                                                                                                                                                                                                                                                                                                                                                                                       
  Americas                                                               6                                                                                                          ref                                                                                         5            ref                         3             ref                             3           ref                 
  Africa                                                                 0                                                                                                          ---                                                                                         0            ---                         1    −2.09    0.12      0.00--7.55     0.30   1   −2.19   0.11   0.03--0.37    0.01
  Eastern Mediterranean                                                  0                                                                                                          ---                                                                                         1    −0.51   0.60   0.00--96.20   0.83   2    3.29    26.91    0.60--1212.80    0.09   0           ---                 
  Europe                                                                 6                                                  −0.51                                                   0.60                                                0.24--1.49                       0.25   3    0.43    1.54   0.07--35.60   0.76   14   −0.12    0.89      0.08--9.83     0.92   3   −0.33   0.72   0.24--2.16    0.45
  South east Asia                                                        1                                                  −0.32                                                   0.72                                                0.08--6.49                       0.75   3    0.60    1.82   0.07--50.27   0.69   0             ---                             1   0.81    2.26   0.32--15.96   0.31
  Western Pacific                                                        3                                                  −0.49                                                   0.61                                                0.16--2.36                       0.44   2    −0.81   0.45   0.02--10.30   0.58   4    −1.60    0.20      0.01--3.23     0.24   1   −0.39   0.67   0.20--2.26    0.42

Regression coefficient from metaregression.

To examine if there were significant differences between subgroups, we conducted four meta-regression analyses testing each subgroup within the four groups: (i) maternal infection and neonatal infection, (ii) maternal colonization and neonatal infection, (iii) maternal colonization and neonatal colonization, and (iv) maternal risk factors and neonatal infections. Mothers with GBS colonization had a higher odds of having newborns with GBS colonization compared to mothers with *E. coli* colonization having newborns with *E. coli* colonization (OR = 12.9, 95% CI 1.2--143.4). There were no significant differences between other subgroups.

Discussion {#s5}
==========

We found consistent evidence of higher levels of early-onset neonatal infection among newborns of mothers with bacterial infection or colonization compared to newborns of mothers without infection or colonization. Although this relationship has long been understood, the magnitude of the disproportionate risk for infection has not yet been systematically documented. In studies with the most definitive measures of infection ("lab/lab"), newborns of infected mothers had a seven times higher odds of early-onset neonatal infection compared to newborns of uninfected mothers. Excluding high-risk-of-bias studies, the odds of neonatal infection increased to nine times higher among newborns of infected mothers compared to newborns of uninfected mothers.

We included studies that measured clinical signs or risk factors of infection and compared estimates from these studies with estimates from studies with the gold standard lab-confirmed measures. In studies that tested neonatal lab cultures and diagnosed maternal infection with clinical signs ("signs/lab"), the OR was similar (with overlapping confidence intervals) to studies that diagnosed maternal infection with lab cultures ("lab/lab"), suggesting that maternal clinical signs may reliably identify maternal infections. Future studies could test the sensitivity and specificity of using maternal clinical signs to diagnose maternal infections. In studies documenting maternal risk factors, newborns of mothers with risk factors had higher odds of infection than newborns of mothers without risk factors, although this association was weaker in studies with maternal risk factors compared to studies with maternal lab-confirmed or clinical signs of infection.

Maternal colonization with GBS has been shown to increase the odds of neonatal sepsis [@pmed.1001502-Benitz1]. In this review, most studies that tested maternal colonization cultured for GBS. Colonization at delivery was associated with early-onset lab-confirmed neonatal infection, although we found a smaller effect (OR 11.0, 95% CI 3.6--33.5) than in a prior review on GBS colonization and neonatal infection published on developed countries (OR 204, 95% CI 100--419) [@pmed.1001502-Benitz1]. In studies measuring maternal and neonatal colonization, there was strong evidence for increased odds of surface colonization among newborns of colonized mothers, supporting the idea that there is direct transmission through contact between the mother and newborn during delivery.

In studies with neonatal clinical signs of infection, the magnitude of the association was smaller compared to studies with neonatal lab-confirmed infection. Neonatal clinical signs may not be specific enough to detect strong associations between maternal and neonatal infections. Studies that diagnosed neonatal infection with a more comprehensive definition, neonatal lab or clinical signs of infection, had a higher OR than studies with neonatal lab alone or clinical signs alone. Laboratory cultures may underestimate the true risk of early-onset neonatal infection because their sensitivity of detecting bacteria is dependent on several factors such as the volume of the specimen collected, timing of collection, technique used, and dilution methods [@pmed.1001502-Connell1],[@pmed.1001502-Edmond1].

Studies with laboratory-confirmed infections were limited, especially from African and southeast Asian regions, and this presents challenges in estimating the global risk of infection among newborns of infected mothers. Because lab-confirmed data were not available in some regions, we looked at additional measures of infection such as clinical signs of infection, risk factors for infection, and colonization with the understanding that each measure of infection varied by completeness and accuracy. While this presented a comprehensive review of the literature, it also created significant heterogeneity among the studies included in the meta-analysis. To minimize heterogeneity, we grouped studies by exposure and outcome definitions and conducted separate meta-analyses for each group. To account for additional differences, we used a random-effects model. We did not provide an overall estimate measure across all studies because we assessed the studies to be too heterogeneous. Several subgroup analyses had high I^2^ values suggesting most of the variability across included studies is due to heterogeneity. We included pooled estimates for all subgroup analyses and I^2^ values and I^2^ confidence intervals to allow the reader to consider the extent of heterogeneity when interpreting these results. Since all studies were facilities-based and mostly concentrated in urban settings in the Americas and Europe, we were not able to capture the risk of neonatal infection among home births, rural births, or births at community facilities in lower-income countries, thereby limiting the generalizability of these findings.

Furthermore, most studies included in the review were assessed to be at high or unclear risk of bias, which may lead to an underestimation or overestimation of the true effect. We used sensitivity analyses to exclude high-risk-of-bias studies and specifically examined confounding bias. After excluding studies with high risk of confounding bias, the magnitude of our effect size increased, suggesting that negative confounders may have biased results towards the null. There were limited data available on intrapartum antibiotic use. The inclusion of individuals who received antibiotics would lead a study to underestimate the magnitude of the association. When possible, we conducted sensitivity analyses including only studies with data where it was clear there was no antibiotic use. Lastly, we repeated the analyses with studies that specified an early-onset neonatal period of less than 7 d, which was associated with an increased risk of transmission. Misclassification of neonatal sepsis cases in the late-onset period likely underestimated our effect size, suggesting that these cases were unlikely to be maternally acquired. Finally, classification of studies by WHO region combines disparate countries but was performed to be consistent with past literature, and limited sample sizes resulted in wide confidence intervals, limiting the precision of our estimates.

This study has important policy and research implications. The risk of early neonatal infection among women with maternal infections is high and presumably even higher in low-resource settings where most women deliver at home without access to health care. Intrapartum antibiotic prophylaxis could reduce the incidence of maternally acquired early-onset neonatal infections [@pmed.1001502-Schrag1],[@pmed.1001502-Ohlsson2],[@pmed.1001502-SaezLlorens1]. In settings where the case-fatality of early-onset neonatal sepsis is high, prophylaxis could potentially have a large benefit. Currently, a risk-based algorithm combined with GBS screening exists for use of intrapartum antibiotic prophylaxis in high income countries to prevent GBS early-onset neonatal sepsis. In this algorithm, antibiotics are given during labour to women who screened positive for GBS colonization at 35--37 wk gestation and to women with unknown GBS status and the following risk factors: less than 37 wk gestation, duration of membrane rupture ≥18 h, or temperature ≥38°C [@pmed.1001502-Verani1]. Temporal trends of decreasing GBS incidence have been observed before versus after implementation of these guidelines (1.7 per 1,000 live births in 1993 compared to 0.6 per 1,000 in 1998) [@pmed.1001502-Schrag1]. This algorithm could be expanded to include other pathogens, especially in settings where GBS incidence is low such as southeast Asia (0.02 per 1,000 live births) [@pmed.1001502-Edmond1]. A double-blinded randomized controlled trial testing the use of intrapartum antibiotic prophylaxis on early-onset neonatal sepsis is needed, although this would be expensive. In addition to focusing on the mother, other interventions could include administering antibiotic prophylaxis to newborns of high risk women.

Emphasis should be placed on evaluating methods to diagnose and treat maternal infections and subsequently reducing early neonatal infections. Given the available resources, or lack thereof, in regions like Africa and Asia, better diagnostics and treatment of maternal infections in these settings have the potential to substantially reduce early neonatal infections. Development of a simple algorithm that combines clinical signs and risk factors to diagnose maternal infections would be useful in settings where lab facilities (culture or colonization) are not available.

Conclusion {#s5a}
----------

To our knowledge, this is the first comprehensive review looking at maternally acquired early-onset neonatal infection. Based on the results, there is great potential to reduce early-onset neonatal infections by focusing interventions on women with maternal infections (laboratory-confirmed, clinical signs), colonization, and risk factors for infection (PROM, PPROM, and prolonged ROM). There is a need to understand the etiology of both maternal infections and colonization and neonatal infections in low- and middle-income countries. Standardizing definitions for maternal infections and newborns would be helpful to compare studies. High quality studies and better diagnostics are needed in low-resource areas, especially southeast Asia and Africa.

Improving the detection of maternal infections during the intrapartum period using new technologies such as microfluidic assays, proteomic amniotic fluid analysis, or real-time polymerase chain reaction to develop point of care-devices that are cheap, fast, and highly sensitive and specific may allow health care workers to reach at-risk newborns sooner. In the meantime, improving identification of clinical signs and risk factors for maternal infection will have more immediate benefits, particularly in resource-limited settings. Although this review emphasizes targeting mothers to prevent neonatal infections, a comprehensive package would also focus on early detection of early-onset neonatal sepsis and neonatal treatment to decrease mortality and morbidity from neonatal infections during the first 7 d of life.

Supporting Information {#s6}
======================

###### 

**Funnel plot with 95% CIs to assess for publication and small-study bias.**

(TIF)

###### 

Click here for additional data file.

###### 

**Risk of bias summary for association measure: 77 cohort and nested case-control studies; six case-control studies.**

(PDF)

###### 

Click here for additional data file.

###### 

**Search terms by database.**

(PDF)

###### 

Click here for additional data file.

###### 

**Authors contacted regarding missing data.**

(XLSX)

###### 

Click here for additional data file.

###### 

**Full text non-English articles screened.**

(XLSX)

###### 

Click here for additional data file.

###### 

**Studies included in systematic review and meta-analysis: Maternal exposure and neonatal outcome combinations, relative risks, and definitions.**

(PDF)

###### 

Click here for additional data file.

###### 

**PRISMA statement.**

(DOC)

###### 

Click here for additional data file.

###### 

**Study protocol.**

(DOCX)

###### 

Click here for additional data file.

We thank Swaroop Vedula, Kristina Lindsley, Tianjing Li, and Kay Dickersin at the Center for Clinical Trials at Johns Hopkins University for their expertise in systematic reviews and meta-analysis. We also thank Jennifer Robinson, Vivek Charu, and Ann Tukpah for reviewing and abstracting data. Alexo Esperato and Naoko Kozuki reviewed the non-English articles. We acknowledge Kate Lobner for developing and running the search strategy. We would like to thank the mothers and newborns who participated in these studies to better understand the causes and modes of transmission of early-onset neonatal sepsis.

GBS

:   Group B streptococcus

OR

:   odds ratio

PPROM

:   preterm prelabour rupture of membranes

PROM
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